Physician profile
Ayman Alibrahim
NPI 1063469104
$9,416.21
in general payments reported to CMS, 2019-2025
27 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $641 · 2021: $1,063 · 2022: $1,441 · 2023: $1,826 · 2024: $1,833 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,494 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.79 |
| Education | $188.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,988.54 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,378.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,315.34 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,190.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $606.01 | 2020-2025 | Cuvitru, Hyqvia |
| Amgen INC. | $536.39 | 2021-2025 | Tezspire |
| Csl Behring | $519.58 | 2022-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $357.69 | 2021-2025 | |
| Grifols USA, LLC | $257.64 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $154.90 | 2023-2025 | |
| Pfizer INC. | $152.24 | 2019-2025 | |
| Leo Pharma INC. | $135.35 | 2022-2025 | Adbry |
| Genentech USA, INC. | $125.03 | 2021-2023 | Xolair |
| Octapharma USA, INC. | $98.38 | 2021 | |
| Mylan Specialty L.P. | $85.27 | 2020-2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $76.98 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $75.45 | 2020-2024 | Ruconest |
| Hikma Pharmaceuticals USA | $54.51 | 2024-2025 | Ryaltris |
| Shire North American Group INC | $51.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.85 | 2021 | |
| Lilly USA, LLC | $47.53 | 2024-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $46.70 | 2025 | Nemluvio |
| Kaleo, INC. | $33.49 | 2022-2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $24.49 | 2020 | |
| Phadia US INC. | $20.00 | 2023 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $19.41 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Alibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.